Nicola Simoni

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Radiotherapy as an antihemorrhagic approach in gastric cancer: the RANTIGA study.

Radiotherapy as an antihemorrhagic approach in gastric cancer: the RANTIGA study.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: March 10, 2026

Conventionally Fractionated Radiotherapy (CFRT) Versus Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Comparative Studies.

Conventionally Fractionated Radiotherapy (CFRT) Versus Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Comparative Studies.

Journal: Cancers

Published: February 02, 2026

Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation Therapy.

Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation Therapy.

Journal: European urology oncology

Published: September 27, 2025

Penalized-Survival Nomogram Predicts 5-Year Metastasis-Free Survival After Salvage Radiotherapy for Postprostatectomy Patients: A Multicenter Study.

Penalized-Survival Nomogram Predicts 5-Year Metastasis-Free Survival After Salvage Radiotherapy for Postprostatectomy Patients: A Multicenter Study.

Journal: Clinical genitourinary cancer

Published: June 18, 2025

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 23, 2025

Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).

Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).

Journal: La Radiologia medica

Published: April 08, 2025

External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma.

External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma.

Journal: Technology in cancer research & treatment

Published: March 25, 2025

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature.

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature.

Journal: JTO clinical and research reports

Published: February 26, 2025

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Journal: Immunotherapy

Published: January 20, 2025

The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review.

The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review.

Journal: Oncology research

Published: August 13, 2024

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney.

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney.

Journal: Clinical genitourinary cancer

Published: July 18, 2024

PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.

PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.

Journal: Medical oncology (Northwood, London, England)

Published: October 24, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026